| Phase 15 trials |
|
Phase 1
|
NCT04793204 |
Mar → May 2021 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04641260 |
Nov 2020 → Feb 2021 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04482270 |
Sep 2020 → Mar 2021 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04476849 |
Aug 2020 → Mar 2022 |
impaired renal function disease |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03436849 |
Feb → May 2018 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
| Phase 28 trials |
|
Phase 2
|
NCT07568236 |
Jul 2026 → Dec 2027 expected |
prostate cancer |
Chinese University of Hong Kong |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06957691 |
Jan 2026 → Aug 2028 expected |
metastatic prostate carcinoma, prostate adenocarcinoma |
Shehzad Basaria, M.D. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06972875 |
Dec 2025 → Jan 2027 expected |
prostate cancer |
University of Vermont |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06812754 |
Mar 2025 → Feb 2026 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06617455 |
Oct 2024 → Oct 2025 |
ductal breast carcinoma in situ, female breast carcinoma |
University of Michigan Rogel Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT05034042 |
Nov 2021 → Nov 2022 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03192176 |
Jul 2017 → Sep 2018 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05419908 |
Sep 2015 → Sep 2016 |
— |
Ogeda S.A. |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT06975111 |
Mar 2026 → Oct 2029 expected |
cardiovascular disorder |
University of Colorado, Denver |
Recruiting
|
No outcome recorded
|
| Phase 310 trials |
|
Phase 3
|
NCT07606664 |
Sep 2026 → Nov 2029 expected |
premature menopause |
Rebecca Thurston |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06440967 |
Jul 2024 → Jun 2026 overdue |
— |
Astellas Pharma Global Development, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06206421 |
Feb 2024 → Mar 2026 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT06206408 |
Feb 2024 → Oct 2025 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05033886 |
Nov 2021 → Mar 2023 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04451226 |
Jul 2020 → Jun 2022 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04234204 |
Mar 2020 → Apr 2022 |
— |
Astellas Pharma Inc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04003155 |
Jul 2019 → Oct 2020 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04003389 |
Jul 2019 → Jan 2022 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04003142 |
Jul 2019 → Jul 2020 |
— |
Astellas Pharma Global Development, Inc. |
Completed
|
No outcome recorded
|